Companies / NC6

NANOLLOSE LIMITED

ASX:NC6Pharmaceuticals, Biotechnology & Life Sciences
409.0M shares on issueASX (delayed) · as of 28 July 2026$0.076price · delayed$31.1Mmarket cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 138% in 24 months; 2 cash raises in 24 months

Cash runway-0.1 quarters of funding
Share-count growth (24m)137.8%
Raise cadence (24m)2 cash raises
Options & rights overhang26.6% of shares
In-the-money supply4.5% of shares
Pending proposed issuesnone

NANOLLOSE LIMITED's ordinary share count grew 137.8% between February 2024 and May 2026, to 409M shares. The company raised capital twice in that 24-month window for total proceeds of A$1.1M, most recently raising A$878K in May 2025. Options and rights on issue could convert into 109M new shares, equal to 26.6% of the current share count, of which 4% are in the money at the current share price; the nearest expiry is February 2027. At the March 2026 quarter the company reported A$-48K in available cash, representing -0.1 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
26.6%
Max option dilution
4.5%
ITM option dilution
0
Raises · last 12 months
-0.1 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 409.0M per ASX (delayed) (28 July 2026).
221.8M290.5M359.2MDec 24Sept 25July 26Cash raise · 19 May 2025Cash raise · 30 Apr 2025

Cash runway

-0.1 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$-48k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
29 May 20262A · quoted issueNC6 : ORDINARY FULLY PAID409.0MAppendix 2A
5 May 20262A · quoted issueNC6 : ORDINARY FULLY PAID408.9MAppendix 2A
30 Apr 20262A · quoted issueNC6 : ORDINARY FULLY PAID349.5MAppendix 2A
30 Apr 20262A · quoted issueNC6 : ORDINARY FULLY PAID350.9MAppendix 2A
28 Apr 20262A · quoted issueNC6 : ORDINARY FULLY PAID349.4MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 0 in the last 12 months

$878k
Capital raise
19 May 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

26.6%
Total overhang · of current shares
4.5%
In the money · at current price
108.8M
Potential new shares
Feb 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
3 Dec 2025Ms Heidi BeattyOther—1.0M—3Y notice
1 Nov 2025Mr Winton WilleseeSell———3Y notice
1 Aug 2025Mr Andrew MoullinBuy100k30.0M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

29 May 2026Application for quotation of securities - NC6
19 May 2026Becoming a substantial holder
12 May 2026Change in substantial holding
12 May 2026Change in substantial holding
5 May 2026$1.58m in New Funding Raised Through Option Conversions
5 May 2026Application for quotation of securities - NC6
30 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
30 Apr 2026Application for quotation of securities - NC6
30 Apr 2026Application for quotation of securities - NC6
28 Apr 2026Application for quotation of securities - NC6
23 Apr 2026Application for quotation of securities - NC6
23 Apr 2026Application for quotation of securities - NC6
21 Apr 2026Progress Across Facility Development and Process Improvement
21 Apr 2026Application for quotation of securities - NC6
17 Apr 2026Application for quotation of securities - NC6
16 Apr 2026Application for quotation of securities - NC6
13 Apr 2026Application for quotation of securities - NC6
7 Apr 2026Letter to Shareholders
7 Apr 2026Application for quotation of securities - NC6
1 Apr 2026Final Director's Interest Notice

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.